Puts puts puts baby
08-27

While the $9.2B peak sales model for intismeran provides strong long-term validation for Moderna’s mRNA platform beyond COVID-19, chasing a 14% single-day pop driven by a broker upgrade from Underperform to Neutral carries high near-term risk. Without published Phase 3 trial specifics or signed commercial contracts, current pricing reflects speculative future potential while LTM revenue remains down 27.6% y/y at $2.23B. The safer play is rotating into Merck, which split-funds the therapy and provides immediate downside protection via Keytruda cash flows, or simply waiting for detailed clinical data before building a core position in Moderna.

Cancer Vaccine Valued at $9.2B Peak Sales — Can Moderna Hold a 14% Gain?
Moderna +14.36% to $158.83 Tuesday after Wolfe Research moved it from Underperform to Peer Perform — a 14% move on an upgrade to neutral, which shows how empty positioning was — modeling peak sales near $9.2bn for intismeran. Barclays raised its target to $125, still below the current price. The pricing has migrated: the first 176.97% was short covering, this leg prices annual revenue potential. Against it: full data unpublished, peak sales are model assumptions not orders, LTM revenue $2.23bn and down 27.6%. Build on the $9.2bn thesis, rotate to Merck, or wait for the data?
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment